Cargando…
Unmasking of myoclonus by lacosamide in generalized epilepsy
Lacosamide is a new-generation antiseizure medication that is approved for use as an adjunctive treatment and monotherapy in focal epilepsy. Its use in generalized epilepsy, however, has not been adequately evaluated in controlled trials. We report a 67-year-old woman who experienced new-onset myocl...
Autores principales: | Birnbaum, Daniel, Koubeissi, Mohamad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318289/ https://www.ncbi.nlm.nih.gov/pubmed/28239547 http://dx.doi.org/10.1016/j.ebcr.2016.09.006 |
Ejemplares similares
-
Multifocal myoclonus as a presentation of levetiracetam toxicity
por: Bou Nasif, Mei, et al.
Publicado: (2021) -
Efficacy of Lacosamide in a Patient with Refractory Generalized Epilepsy Based on Video Electroencephalography
por: Yamada, Hidetada, et al.
Publicado: (2021) -
Ventricular tachycardia associated with lacosamide co-medication in drug-resistant epilepsy()
por: DeGiorgio, Andrew C., et al.
Publicado: (2012) -
Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy
por: Cuomo, Ilaria, et al.
Publicado: (2017) -
Juvenile Huntington’s disease masquerading as progressive myoclonus epilepsy
por: Thakor, Bina, et al.
Publicado: (2021)